Top 10 stocks for today – 24th January 2024

24 Jan 2024 , 08:29 AM

Here are some of the stocks that may see significant price movement today.

1. Axis Bank: The private sector lender disclosed a 3.7% year-on-year increase in net profit, reaching Rs 6,071.1 crore for the third quarter ending on December 31, 2023.
2. Pidilite Industries: The company reported a robust 66% increase in its consolidated net profit, reaching Rs 510.92 crore in the December 2023 quarter. Revenue from operations also exhibited growth, rising by 4.41% to Rs 3,130 crore during the quarter, compared to Rs 2,997.59 crore in the corresponding period a year ago.
3. Indus Towers: The telecom infrastructure major disclosed a consolidated net profit of Rs 1,540.1 crore for the third quarter ending on December 31, 2023.
4. Havells: The domestic consumer appliances major posted a marginal year-on-year increase of 1.4% in net profit, totaling Rs 287.9 crore for the third quarter concluding on December 31, 2023.
5. JSW Energy: The company posted a consolidated net profit of over Rs 231 crore in the December 2023 quarter, reflecting a substantial growth of over 28% due to increased revenues. Total revenue for the quarter rose by 13% year-on-year, reaching Rs 2,661 crore compared to Rs 2,350 crore in Q3 FY23.
6. United Spirits: The liquor maker under Diageo’s control recorded a substantial year-on-year surge of 63.5% in net profit, reaching Rs 350.2 crore for the third quarter concluding on December 31, 2023.
7. Karnataka Bank: The private sector lender disclosed a 10% year-on-year increase in net profit, reaching Rs 331 crore for the third quarter concluding in December 2023. In the same quarter of 2022, the bank had reported a net profit of Rs 301 crore.
8. Tata Elxsi: The design-oriented technology services provider has reported a net profit of Rs 206.4 crore for the October-December quarter of FY24, marking a 3.2% increase over the preceding quarter, despite facing challenges in operating margin.
9. Cyient DLM: EMS firm posted a year-on-year increase of 21.6% in net profit, reaching Rs 6.2 crore for the third quarter ending on December 31, 2023.
10. Lupin: The leading pharmaceutical company secured provisional approval from the USFDA on January 23 for rivaroxaban tablets. This medication, granted tentative approval by the USFDA, acts as a generic counterpart to Xarelto Tablets produced by Janssen Pharmaceuticals, Inc.